RedHill Biopharma (RDHL) to Voluntarily Delist from Tel-Aviv Stock Exchange
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
RedHill Biopharma (RDHL) Tops Q3 EPS by 41c
November 19, 2019 7:05 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.03, $0.41 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.77 million.
Financial highlights for the quarter ended September 30, 2019:
Net Revenues of $1.4 million in the third quarter of 2019, compared to $1.6 million in the second quarter of 2019. Gross Profit of $0.8 million in the third quarter of 2019, compared to $1.1 million in the second quarter of 2019. Research and Development Expenses of $2.8 million in the third quarter of 2019, compared to $7.0 million in the second quarter of 2019.... More